BIND Therapeutics
Healthcare
Biotechnology
Life sciences
Health care
Health, wellness & fitness
Biotechnology
Public companyFounded in 2006
Cambridge, Massachusetts
BIND Therapeutics information
BIND Therapeutics is a biotechnology company incorporated in 2006; Pfizer acquired substantially all of its assets in 2016. BIND's product candidates were based on proprietary polymeric nanoparticles called ACCURINS®, which are engineered to target specific cells and tissues in the body at sites of disease. ACCURINS®, which continue to be developed with Pfizer, have the potential to achieve therap...
BIND Therapeutics is a biotechnology company incorporated in 2006; Pfizer acquired substantially all of its assets in 2016. BIND's product candidates were based on proprietary polymeric nanoparticles called ACCURINS®, which are engineered to target specific cells and tissues in the body at sites of disease. ACCURINS®, which continue to be developed with Pfizer, have the potential to achieve therapeutic outcomes not currently possible with conventional treatment modalities.
Employees
Looking for a particular BIND Therapeutics Employee?
Employee Metrics
BIND Therapeutics' financial review
BIND Therapeutics' Revenue (Yearly)
14.8M
Nasdaq
BIND
Employees
5
Market cap
104.7M
Technologies
Alumni
Employees
Looking for a particular BIND Therapeutics Employee?
BIND Therapeutics' financial review
BIND Therapeutics' Revenue (Yearly)
14.8M
Nasdaq
BIND
Employees
5
Market cap
104.7M
Prospect on LinkedIn
Find verified emails and direct dial mobile numbers of contacts on LinkedIn, and sync them with your CRM instantly
